Stocktoria
Armata Pharmaceuticals, Inc. ARMP
Armata Pharmaceuticals, Inc. (ARMP) earns a Piotroski F-score of 3/9 (weak financial health). It pays a dividend yielding 0.03% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ARMP | Armata Pharmaceuticals, Inc. | 3/9 | — | — | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
FAQ
Is ARMP financially healthy?
Armata Pharmaceuticals, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ARMP pay a dividend, and is it safe?
Yes. Armata Pharmaceuticals, Inc. pays a dividend yielding about 0.03% with a None payout ratio, rated “no dividend” for safety.
What is the analyst price target for ARMP?
The average Wall-Street price target for Armata Pharmaceuticals, Inc. is $17.50, about 306.0% above the recent price, from 2 analysts.
Is ARMP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Armata Pharmaceuticals, Inc.: a Piotroski F-score of 3/9, a dividend yield of 0.03%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.